ANCA-positive vasculitis

Journal of the American Society of Nephrology

Volumn 13, Issue 7, 2002, Pages 1953-1960

  Ritz, Eberhard ^a   Kamesh, Lavanya ^a   Harper, Lorraine ^a   Savage, Caroline O S ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; ENDOTHELIUM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAINTENANCE THERAPY; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VASCULITIS;

EID: 0036293330     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000016442.33680.3E     Document Type: Article

References (64)

1. Nomenclature of systemic vasculitides: The proposal of an International Consensus Conference
2. Primary systemic vasculitis
3. Epidemiology of systemic vasculitis, increasing incidence?
4. Pathogenesis of ANCA-associated systemic vasculitis
5. New findings in pathogenesis of ANCA-associated vasculitis
6. Evidence for the role of T cells in the pathogenesis of systemic vasculitis
7. Primary systemic vasculitis
8. The vasculitides
9. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
10. International Consensus Statement on testing and reporting of antineutrophil cytolasmic antibodies (ANCA)
11. Wegener's granulomatosis: An analysis of 158 patients
12. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
13. An interdisciplinary approach to the care of patients with Wegener's granulomatosis
14. Treatment response and relapse in ANCA-associated microscopic polyangiitis and glomerulonephritis
15. Activity, damage and outcome in systemic vasculitis
16. Update on the European Vasculitis Study Group trials (EUVAS)
17. The value of pulse cyclophosphamide in ANCA-associated vasculitis. Meta-analysis and critical review
18. Plasma exchange in focal necrotising glomerulonephritis without anti-GBM antibodies
19. Neutrophil priming and apoptosis in ANCA-associated vasculitis
20. Methylprednisolone normalises superoxide anion production by the polymorphs from patients with ANCA-positive vasculitis
21. Infection and immunosuppression: A study of the infective complications of 75 patients with immunologically mediated disease
22. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
23. G-CSF treatment for cyclophosphamide induced severe neutropenia in Wegener's granulomatosis
24. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisolone as the initial therapy of choice
25. An analysis of 42 Wegener's granulomatosis patients treated with methotrexate and prednisolone
26. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis
27. High rate of renal relapses in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate
28. The role of de novo purine synthesis in lymphocyte transformation
29. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules
30. Mycophenolate Mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
31. Preliminary results of a pilot study on the use of mycophenolate mofetil in relapsing ANCA small-vessel vasculitis
32. Mycophenolate mofetil therapy in anti-neutrophil cytoplasmic antibody vasculitis
33. Mycophenolate mofetil for remission induction in patients with active Wegener's granulomatosis intolerant to cyclophosphamide
34. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure
35. Plasma exchange and cyclosporin A in Wegener's granulomatosis - A controlled study
36. Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis
37. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease
38. In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis
39. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10
40. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis
41. Serum concentrations of neopterin, soluble tumour necrosis factor receptor in Wegener's granulomatosis
42. Activated neutrophils express Pr3 on their plasma membrane in vitro and in vivo
43. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis
44. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides?
45. The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm antibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation
46. Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages
47. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1α expression in 15 cases of antineutorphil cytoplasmic autoantibody-associated renal vasculitis
48. Glomerular vascular cell adhesion molecule-1 expression in renal vasculitis
49. Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor a antibody in rheumatoid arthritis
50. Decreased cellularity and expression of adhesion molecules in rheumatoid synovial tissue after anti-TNF-α monoclonal antibody treatment
51. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor
52. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six month open-label trial to evaluate safety
53. A disease specific asctivity score for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score
54. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin
55. Anti-thymocyte globulin in a patient with pANCA vasculitis and crescentic glomerulonephritis
56. Treatment of refractory Wegener's granulomatosis with humanised monoclonal antibodies
57. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin
58. Durable donor specific T and B cell tolerance in rhesus macaques induced with per-transplantation anti-CD3 immunotoxin and deoxyspergualin
59. 15-Deoxyspergualin for refractory Wegener's granulomatosis and microscopic polyangiits: Results of a multicentre trial
60. Autologous haemopoetic stem cell transplants for autoimmune disease - Feasibility and transplant related mortality
61. New therapeutic aspects: Haemopoietic stem cell transplantation
62. Novel therapies for ANCA-associated vasculitis
63. Response of Wegener Granulomatosis to anti-CD20 chimeric monoclonal antibody therapy